Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxilofrine is a sympathomimetic small molecule and amphetamine derivative used primarily as an antihypotensive agent and antitussive. It acts as a norepinephrine releasing agent, indirectly stimulating both alpha and beta adrenergic receptors, with predominant activity at the beta-1 adrenergic receptor. This results in increased myocardial contractility (positive inotropic effect), elevated heart rate, vasoconstriction via alpha-1 activation, and increased blood pressure. Oxilofrine has been used to treat low blood pressure (hypotension), manage asthma exacerbations, suppress cough associated with inflamed mucosa (often in combination products), and enhance cardiac function during anesthesia. It is not approved for use in the United States but has been marketed under various brand names internationally[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxilofrine.